ClinicalTrials.gov
ClinicalTrials.gov Menu

The Role of Immature Myeloid Cells, Monocytes, Dentritic Cells and Neutrophils in Human Pregnancies as Markers for Mature Pregnancy and Spontaneous Labor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02361853
Recruitment Status : Unknown
Verified January 2015 by Hillel Yaffe Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : February 12, 2015
Last Update Posted : February 12, 2015
Sponsor:
Information provided by (Responsible Party):
Hillel Yaffe Medical Center

Brief Summary:

Accumulating evidence suggest that the proliferative, invasive, and immune tolerance mechanisms that malignant tumors use to establish a nutrient supply and evade or edit the host immune response are similar to those used by the developing placenta during normal pregnancy. In addition to the shared capacity for invading through normal tissues, both cancer cells and cells of the developing placenta create a microenvironment supportive of both immunologic privilege and angiogenesis.

CD11b+Gr1+ cells are a heterogeneous population of bone marrow-derived cells (BMDC) that consist of immature myeloid cells (IMCs), and were first described as myeloid-derived suppressor cells. In healthy individuals, IMCs that are generated in the bone marrow differentiate into mature granulocytes, macrophages, or dendritic cells (DCs). These cells have been shown to play an essential role in mediating immune suppression in animal models of human tumors. As a result of tumor-induced alterations in myelopoiesis, IMCs have been found in peripheral blood, lymphoid organs and the tumor tissue itself. An increased population of IMCs was identified in patients with several tumor types. Accordingly, IMCs detected in the peripheral blood of such patients bearing express the common myeloid marker CD33 but lack markers of mature myeloid cells such as the MHC class II molecule HLADR.

IMCs have been shown to actively promote tumor growth and metastasis by modulating the cytokine environment, and through vascular remodeling by promoting angiogenesis.

It has been demonstrated in our laboratory that IMCs infiltrate placentas of pregnant mice and actively promote angiogenesis. These cells show striking similarity to IMCs that populate malignant tumors. Accordingly, human placentas are also infiltrated by a significant population of IMCs. Immunostaining of human placentas showed that IMCs comprise around 25% ( range 10-40%) of total placental CD45+ bone marrow-derived hematopoietic cells and that this population is located close to blood capillaries. The investigators also demonstrated that immature DCs, cells originally described to regulate the adaptive immune response, also promote angiogenesis in models of choroidal neovascularization, endometriosis and tumors.

Tho objective in this proposed study is to compare the abundance of IMC, DC, monocytes and neutrophils counts in blood samples of normal pregnancies: 1. in women in term active labor. 2. In women not in labor. 3. In pre term labor.

According to our previous findings, the investigators hypothesize that IMC's, monocytes and in active delivery (both term and pre term) will be lower than women without signs for labor. The investigators also hypothesize that DC's and neutrophils will be more abundant in active delivery (in term and pre term) than women without signs for labor.

Experimental plan:

Blood count will be collected from pregnant women who agree to participate in the research:

The samples will be sent for the routine complete blood count in Hillel Yaffe hematologic lab and also will be analyzed for IMC's and DC's population in our lab using fluorescent immunostaining with specific monoclonal antibodies and flow cytometry.

IMC's per total CD45 positive hematopoietic cells from the placental tissue will be analyzed using fluorescent immunostaining with specific monoclonal antibodies and flow cytometry . The specific location of these cells in the placenta will be identified within the placental tissue using Immunohistochemistry (IHC). The expression of pro angiogenic genes will be analyzed by RT PCR and Western blotting.


Condition or disease Intervention/treatment
Parturition Other: Exposure: abundance of Immature Myeloid Cells counts in blood samples Other: Exposure: abundance of Immature Dentritic Cells counts in blood samples Other: Exposure: abundance of Immature monocytes counts in blood samples Other: Exposure: abundance of Immature neutrophils counts in blood samples

Study Type : Observational
Estimated Enrollment : 60 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Role of Immature Myeloid Cells, Monocytes, Dentritic Cells and Neutrophils in Human Pregnancies as Markers for Mature Pregnancy and Spontaneous Labor
Study Start Date : March 2015
Estimated Primary Completion Date : March 2016
Estimated Study Completion Date : March 2017

Group/Cohort Intervention/treatment
Active labor at term
Women in active labor normal pregnancy at term
Other: Exposure: abundance of Immature Myeloid Cells counts in blood samples
Other: Exposure: abundance of Immature Dentritic Cells counts in blood samples
Other: Exposure: abundance of Immature monocytes counts in blood samples
Other: Exposure: abundance of Immature neutrophils counts in blood samples
Non-active labor at term
Women, normal pregnancy at term who come for usual follow up without signs for labor ( contraction / "show" discharge/ rupture of membranes).
Other: Exposure: abundance of Immature Myeloid Cells counts in blood samples
Other: Exposure: abundance of Immature Dentritic Cells counts in blood samples
Other: Exposure: abundance of Immature monocytes counts in blood samples
Other: Exposure: abundance of Immature neutrophils counts in blood samples
Active labor, pre-term
Women in active pre term labor (34- 37w) normal pregnancy.
Other: Exposure: abundance of Immature Myeloid Cells counts in blood samples
Other: Exposure: abundance of Immature Dentritic Cells counts in blood samples
Other: Exposure: abundance of Immature monocytes counts in blood samples
Other: Exposure: abundance of Immature neutrophils counts in blood samples



Primary Outcome Measures :
  1. Spontaneous labor [ Time Frame: maximum two weeks ]

Biospecimen Retention:   Samples Without DNA
Blood sample.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Pregnant women from: 34 weeks to 42 weeks
Criteria

Inclusion Criteria:

  • Women in active labor normal pregnancy at term.
  • Women, normal pregnancy at term who come for usual follow up without signs for labor ( contraction / "show" discharge/ rupture of membranes).
  • Women in active pre term labor (34- 37w) normal pregnancy.

Exclusion Criteria:

  • Unwilling of the women to participate in the research
  • Signs for infection ( fever >38)
  • Women in pre-term birth under 34 weeks.
  • Administration of Celeston in 2 weeks prior to enrollment.
  • Any complication to the women or fetus which require induction of labor ( Pre-eclampsia, Gestational Diabetes Mellitus A2, pre gestational diabetes, Intrauterine Growth Restriction).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02361853


Contacts
Contact: Rivka Frankel, MD 052-8721581 rivka.lutvack@gmail.com

Sponsors and Collaborators
Hillel Yaffe Medical Center

Responsible Party: Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT02361853     History of Changes
Other Study ID Numbers: 0086-14-HYMC
First Posted: February 12, 2015    Key Record Dates
Last Update Posted: February 12, 2015
Last Verified: January 2015